NCT04295733 - Safety, Tolerability and Immunogenicity of 4CMenB Vaccine(2 Doses) in Adults With an Immunodeficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 6, 2020

Primary Completion Date

January 11, 2024

Study Completion Date

January 11, 2024

Conditions

Acquired Immunodeficiency

Interventions

BIOLOGICAL

4CMenB (Bexsero®) vaccine

Participants will receive 2 doses of 4CMenB (Bexsero®) vaccine administered intramuscularly 1-2 months apart

Trial Locations (1)

U.O.Igiene Ospedale Policlinico San Martino - IRCCS, Genoa